LKEK (Vascular Bioregulator)
LKEK is a synthetic tetrapeptide bioregulator (Leu-Lys-Glu-Lys) investigated for its effects on vascular endothelial function, collagen synthesis regulation, and vascular wall integrity within the Khavinson bioregulatory peptide series.
LKEK (Leu-Lys-Glu-Lys) is a synthetic tetrapeptide belonging to the Khavinson series of bioregulatory peptides developed at the Saint Petersburg Institute of Bioregulation and Gerontology. It has been investigated for tissue-preferential activity in vascular endothelium, where research focuses on endothelial cell function, collagen synthesis regulation in vascular walls, and maintenance of vessel structural integrity during aging.
Overview
Vascular aging involves progressive endothelial dysfunction, loss of vessel wall elasticity, alterations in collagen-to-elastin ratios, and impaired vasodilatory capacity. These changes contribute to atherosclerosis, hypertension, and cardiovascular disease risk. The bioregulatory peptide approach to vascular aging seeks to normalize age-altered gene expression in endothelial and vascular smooth muscle cells, restoring protein synthesis patterns associated with younger, healthier vasculature.
LKEK is part of a broader research program by Khavinson and colleagues that has produced tissue-specific tetrapeptide bioregulators for multiple organ systems. The vascular-targeted members of this series are designed to modulate expression of genes involved in extracellular matrix maintenance, endothelial nitric oxide signaling, and collagen homeostasis in vessel walls.
Mechanism of Action
LKEK's proposed mechanism is consistent with the general bioregulatory peptide framework established by Khavinson (2002), in which short peptides interact with DNA promoter regions to modulate gene transcription in a tissue-context-dependent manner.
Endothelial Gene Expression: In vascular endothelial cells, LKEK is proposed to modulate transcription of genes involved in nitric oxide synthesis, adhesion molecule expression, and endothelial barrier function. The peptide's interaction with accessible chromatin regions in endothelial cells would produce a transcriptional profile favoring vascular homeostasis.
Collagen Synthesis Regulation: Vascular wall integrity depends on balanced collagen synthesis and degradation. Age-related shifts toward excess collagen deposition (fibrosis) or degradation (weakening) contribute to vascular pathology. LKEK research has explored the peptide's capacity to normalize collagen-related gene expression in vascular tissue, maintaining the collagen composition required for vessel wall structural integrity.
Chromatin-Mediated Tissue Specificity: As described by Khavinson et al. (2009), short peptides bind DNA in a sequence-specific manner. The vascular endothelium's distinct chromatin landscape — with active expression of hemostatic, vasomotor, and barrier genes — determines which gene promoters are accessible to LKEK, conferring tissue-preferential activity.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Peptide Bioregulators in Cardiovascular Aging
The cardiovascular system has been a major focus of the Khavinson bioregulatory peptide program. Anisimov et al. (2004) demonstrated that short peptides produce measurable changes in cardiac gene expression profiles, including genes involved in extracellular matrix maintenance and cellular stress responses. The vascular-targeted peptide LKEK extends this approach to the endothelial compartment specifically.
Short Peptide-DNA Interaction Mechanisms
Khavinson et al. (2009) characterized the molecular basis of short peptide-DNA interactions, demonstrating sequence-specific binding in the DNA minor groove. This work provides the structural rationale for how LKEK can modulate gene expression in vascular endothelial cells through direct interaction with accessible promoter regions.
Vascular Endothelial Function and Aging
Endothelial dysfunction is among the earliest detectable changes in vascular aging and a primary driver of cardiovascular disease. Khavinson and Anisimov (2003) reviewed how bioregulatory peptides can modulate organ-specific aging processes, including vascular decline. The normalization of endothelial protein synthesis by short peptides represents a strategy to address endothelial dysfunction at its transcriptional origin rather than through downstream pharmacological intervention.
Bioregulatory Peptides and Collagen Homeostasis
Vascular collagen homeostasis requires coordinated expression of collagen subtypes (primarily types I and III in vessel walls), matrix metalloproteinases, and tissue inhibitors of metalloproteinases. Khavinson (2002) described how short peptides can restore age-diminished protein synthesis in target tissues, a mechanism directly relevant to maintaining the collagen balance required for vascular wall compliance and strength.
Safety Profile
LKEK has been evaluated in preclinical models within the Khavinson bioregulatory peptide research program with no significant adverse effects reported. As a short tetrapeptide composed of natural amino acids (Leu, Lys, Glu, Lys), it is expected to undergo rapid enzymatic degradation. No vascular-specific toxicity has been reported. Formal toxicology studies meeting international regulatory standards have not been published for this specific peptide. The natural amino acid composition and low molecular weight suggest minimal immunogenicity risk, consistent with other members of the Khavinson tetrapeptide series.
Pharmacokinetic Profile
- Half-life
- Not established
Quick Start
- Route
- Subcutaneous injection
Molecular Structure
- Formula
- C₂₂H₄₃N₅O₇
- CAS
- Not established
Research Protocols
subcutaneous Injection
Administered via subcutaneous injection.
Quality Indicators
What to look for
- Multiple peer-reviewed studies available
Frequently Asked Questions
References (6)
- [2]
- [6]Khavinson VK et al Peptide Regulation of Gene Expression and Protein Synthesis in Bronchial Epithelium Molecules (2021)
- [3]Anisimov SV, Khavinson VK, Anisimov VN Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray Neuro Endocrinol Lett (2004)
- [4]
- [1]Khavinson VK Peptides and Ageing Neuro Endocrinol Lett (2002)
- [5]Khavinson VK et al Peptides and Aging Int J Mol Sci (2020)
Livagen
Livagen is a short bioregulatory tetrapeptide that decondenses chromatin to reactivate silenced genes, with research applications in immune system rejuvenation, cardiac health, pain modulation, GI protection, and aging.
LL-37
LL-37 is the only human cathelicidin antimicrobial peptide, playing a critical role in innate immunity through direct antimicrobial activity, immunomodulation, wound healing, and anti-biofilm properties.